A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2‐arachidonoylglycerol with potential anti‐obesity effects | Zendy

Bisogno Tiziana | Zendy; Mahadevan Anu | Zendy; Coccurello Roberto | Zendy; Chang Jae Won | Zendy; Allarà Marco | Zendy; Chen Yugang | Zendy; Giacovazzo Giacomo | Zendy; Lichtman Aron | Zendy; Cravatt Benjamin | Zendy; Moles Anna | Zendy; Di Marzo Vincenzo | Zendy

Premium

A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2‐arachidonoylglycerol with potential anti‐obesity effects

Author(s) -

Bisogno Tiziana,

Mahadevan Anu,

Coccurello Roberto,

Chang Jae Won,

Allarà Marco,

Chen Yugang,

Giacovazzo Giacomo,

Lichtman Aron,

Cravatt Benjamin,

Moles Anna,

Di Marzo Vincenzo

Publication year - 2013

Publication title -

british journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.432

H-Index - 211

eISSN - 1476-5381

pISSN - 0007-1188

DOI - 10.1111/bph.12013

Subject(s) - monoacylglycerol lipase , endocannabinoid system , fatty acid amide hydrolase , 2 arachidonoylglycerol , diacylglycerol lipase , chemistry , cannabinoid receptor , cannabinoid , pharmacology , biochemistry , receptor , antagonist , biology

The development of potent and selective inhibitors of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG) via DAG lipases (DAGL) α and β is just starting to be considered as a novel and promising source of pharmaceuticals for the treatment of disorders that might benefit from a reduction in endocannabinoid tone, such as hyperphagia in obese subjects.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research